0000000000611958

AUTHOR

Barbara Ballmer-weber

showing 2 related works from this author

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

2022

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GALEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international soci…

medicine.medical_specialtyEvidence-based practicehivesmedia_common.quotation_subjectImmunologyeducation610DermatologyAngioedema/diagnosis030207 dermatology & venereal diseases03 medical and health sciencesurticaria0302 clinical medicineQuality of lifeExcellenceimmune system diseasesevidence-basedparasitic diseasesmedicinePrevalenceImmunology and Allergymedia_common.cataloged_instanceHumansitchEuropean unionskin and connective tissue diseaseswhealAsthmamedia_commonAngioedemabusiness.industryangioedemaConsensus conferenceGUIDELINES ; angioedema ; consensus ; evidence2̆010based ; hives ; itch ; mast cell ; urticaria ; whealGuidelinemedicine.diseaseAsthma3. Good healthddc:030228 respiratory systemconsensusFamily medicineChronic DiseaseQuality of LifeUrticaria/diagnosismedicine.symptombusinessmast cell600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.

2016

Background Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen-related food allergy. We aimed to investigate the efficacy of one-year AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birch-related soya allergy. Methods Of 138 subjects with Bet v 1 sensitization, 82 were positive at double-blind placebo-controlled food challenge (DBPCFC) with soya. A total of 56 of 82 were randomized in the ratio of 2:1 (active: placebo). Per-protocol population (PPP) had received ≥150 μg of allergen or placebo preparation. Outcome measures: lowest observed adverse effect levels (LOAEL), postinterventional occurrence of objective signs (objS) at any dose level, sI…

AdultMaleAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyPopulationmedicine.disease_causePlaceboGastroenterology030207 dermatology & venereal diseases03 medical and health sciencessymbols.namesake0302 clinical medicineAllergenFood allergyStatistical significanceInternal medicinemedicineImmunology and AllergyHumanseducationFisher's exact testBetulaSkin Testseducation.field_of_studybusiness.industryRhinitis Allergic SeasonalAntigens PlantImmunoglobulin EMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemDesensitization ImmunologicImmunologysymbolsQuality of LifeFemaleSoybeansbusinessFood HypersensitivityAllergy
researchProduct